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Abstract    
Using the phage display biopanning technique, we have previously identif ied a heptapeptide KLWVIPQ 
which specifically bind to the surface of the IFN-α-sensitive but not the IFN-α-resistant CML cells. The 
effects of this heptapeptide to the IFN-α-sensitive CML cells were investigated in the present study. 
IFN-α-sensitive KT-1/A3 and IFN-α-resistant KT-1/A3R CML cells were transfected by 
pEGFP-KLWVIPQ expression vector and/or induced by IFN-α. WST-1 cell proliferation assay, flow 
cytometry and western blotting were performed to determine the effects of this heptapeptide and/or IFN-α 
on CML cells. The viability of the KT-1/A3 cells was inhibited and apoptosis was induced by either 
expression of the heptapeptide KLWVIPQ or IFN-α treatment with concurrent up-regulation of P53 and 
down-regulation of P210
bcr/abl
. However, these effects were not observed in the IFN-α-resistant KT-1/A3R 
cells. These results suggest that the heptapeptide KLWVIPQ shares a similar mechanism with IFN-α in the 
regulation of CML cell growth and apoptosis, implying that the heptapeptide KLWVIPQ could be a novel 
target to go further into mechanisms of IFN-α sensitivity and/or resistance in CML. 
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Introduction  
Chronic myelogenous leukemia (CML) is a clonal disorder of the multiple pluripotent hematopoietic stem 
cells characterized by Philadelphia (Ph′) chromosome, which results from a reciprocal chromosomal 
translocation [t(9;22)(q34;q11)], in which the bcr gene on chromosome 22 is fused to the c-abl gene on 
chromosome 9, thereby creating a bcr-abl fusion gene 
[1,2]
. The bcr-abl fusion gene encodes a 210-kDa 
hybrid protein known as P210
bcr/abl
,
 
which has strong tyrosine kinase activity, and is deemed to play a 
critical role in tumorigenes is of CML 
[3,4]
. The tyrosine kinase activity of fusion protein P210
bcr/abl
 leads to 
uncontrolled cell proliferation with suppressed apoptosis, and then results in the malignant expansion of  
multipotential hematopoietic stem cells in bone marrow 
[5]
. P210
bcr/abl
 protein activates multiple signal 
transduction pathways such as phosphatidylinositol 3 kinase, Ras/Raf/mitogen-activated protein kinase 
(MAPK), STAT5/Janus kinase pathways to achieve its functions 
[6,7]
.   
 
Interferon-alpha (IFN-α) has been used for decades to treat viral malignancy because of its broad range of 
biologic activities, including mediation of the benefic ial immunomodulatory effects
 [8,9]
, suppression of 
malignant cells proliferation and inducement of apoptosis 
[10]
. Based on inducing hematologic and 
cytogenetic remissions in many patients with CML in chronic phase, IFN-α has been extensively used for 
CML patients treatment in an era 
[11]
, but it fails to effectively induce long-term cytogenetic remission in 
some CML patients 
[12]
. As one of the most effective pharmaceuticals for CML treatment over the past two 
decades, the mechanisms of IFN-α treatment is not fully understood. IFN-α can elicit multiple biologic 
functions because of its diverse signaling pathways, including Rap1, CrkL, VAV, MAP kinase, and 
PI3-kinase 
[13-15]
. Although IFN-α is effective at achieving control of CML in most patients, the resistance 
of CML to IFN-α might emerge de novo or during treatment and ultimately lead to disease progression 
[16]
. 
There are many effective targeting-pharmaceuticals such as tyrosine kinase inhibitor imatinib 
[17,18]
 which 
leads the study and use of IFN-α dramatically reduced in the last decade 
[19]
. It is evident that any 
malignancy is resulted from multiple pathogenic factors, and the related studies show ed that any anticancer 
molecule is not universally effective to tumors 
[20]
. IFN-α, which is associated with a broad range of 
therapeutic effects and influences multiple events, might be more valuable for use in c ombination with the 
other targeting agents to effectively treat leukemia patients than use alone 
[21]
. In a study by Palandri et al 
[22]
, it was suggested that the response to the combination of imatinib with IFN-α is more rapid and 
effective than imatinib alone for treatment of CML in chronic phase. El Eit et al 
[23]
 found that combined 
effects between arsenic and IFN treatment, in vivo can prolong the survival of primary CML mice. Some 
recent findings suggested that IFN-α plus imatinib combination therapy to CML increases the speed and 
rate of responses 
[24-25]
. Katagiri et al 
[26]
 observed that treatment-free molecular remission achieved by 
combination therapy with imatinib and IFN-α in CML with BCL2L11 (BIM) deletion polymorphism 
relapsed after stop imatinib. So, the resistance of CML to the used therapeutics or combination treatment is 
still an observable fact. The further studies for the mechanisms of IFN-α action are needed to clarify the 
best niche for IFN-α use in CML.  
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In an early study, our research group identified some heptapeptides that can specifically bind to the surface 
of IFN-α-sensitive CML cell line KT-1/A3 cells using phage display library 
[27]
. One of the heptapeptides, 
KLWVIPQ, has a partial amino acid sequence homology with the C-terminal domain of E3 
ubiquitin-protein ligase (E3) 
[27]
. In the present study, this heptapeptide KLWVIPQ has been chosen to treat 
IFN-α-sensitive KT-1/A3 and IFN-α-resistant KT-1/A3R cells to explore the regulatory effects of the 
IFN-α-sensitive CML cell-binding heptapeptide KLWVIPQ to proliferation, apoptosis and the related-gene 
expression of CML cells. The results would contribute to a novel target to go further into mechanisms of 
IFN-α sensitivity and/or resistance for clearing the best niche of IFN-α use in CML. 
 
Materials and Methods 
Construction of the recombinant eukaryotic expression vector 
Based on the amino acids sequence of the heptapeptide KLWVIPQ, a specific DNA fragment with the 
sequence of AAG CTG TGG GTA ATC CCA CAG was designed. In order to destine the expressed 
heptapeptide outside of the cell, a DNA fragment encoding the signal peptide (from the Mus musculus 
immunoglobulin heavy chain complex) ATG AAC TTC GGG CTC AGC TTG ATT TTC CTT GTC CTT 
GTT TTA AAA GGT GTC CAG TGT GAA was added in front of the heptapeptide DNA sequence. For the 
purpose of PCR and sub-cloning, extra sequences were added to both ends of the expressing DNA 
sequence to make the DNA fragment in 159 bp length: GCT AGC GCT ACC GGA CTC AGA TC*T CGA 
GCT CAA GCT TCG AAT TCT GCA GTC GAC GGT ACC G ATG AAC TTC GGG CTC AGC TTG 
ATT TTC CTT GTC CTT GTT TTA AAA GGT GTC CAG TGT GAA AAG CTG TGG GTA ATC CCA 
CAG AGT AGT CTA CCG G*TC GC. A pair of PCR primers (Forward: 5’-GCT AGC GCT ACC GGA 
CTC AGA TCT-3’, Reverse: 5’-GCG ACC GGT AGA CTA CTC TGT G-3’) were designed according to 
the underlined sequences. Two restriction sites (Age I and Xho I) were shown as dashed-lines. This DNA 
fragment was synthesized by BGI (China) and cloned into the pEGFP-N1 eukaryotic expression vector 
(Takara, Japan) between the sites of Age I and Xho I. The inserted sequence was confirmed by DNA 
sequencing and the recombinant plasmid was named as pEGFP-KLWVIPQ.  
Cell culture and transfection 
Human CML cell lines KT-1/A3 and KT-1/A3R (kindly provided by Dr. Sakai, Ehime University, Japan) 
were cultured in RPMI1640 medium (GIBCO, USA) with 10% fetal bovine serum (GIBCO, USA) at 37℃ 
with 5% CO2. Cells were transiently transfected with pEGFP-KLWVIPQ and the empty vector pEGFP-N1 
by using Sofast transfection reagent (Sunmabio, China). According to the manufacturer’s instruction of 
transfection reagent kit, the plasmid (2 µg) and reagent (5 µL) were prepared respectively and transferred 
to KT-1/A3 and KT-1/A3R cells on 6-well tissue culture plates with 2 mL of 4×10
5
/mL cell-suspension in 
each well. The transfected cells were cultured in presence or absence of IFN-α (Sigma, USA) in 1000 
U/mL. At 48 h post-transfection, the cells were washed with phosphate buffered saline (PBS) for testing.  
Cell growth assays 
Cell proliferation was measured by using the WST-1 cell proliferation and cytotoxicity assay kit (Beyotime,  
China). Cells were cultured in 96-well plates at 3×10
5
/mL in a total volume of 100 µL for every clone. 
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After 48 h of incubation, 10 µL WST-1 reagents were added into each well, and the cell proliferation rates 
were measured by detecting A450 values. Mean and standard deviation were calculated from triplicate 
experiments. Flow cytometry was employed for checking apoptosis rates of the transfected cells.  
Gene expression analysis  
Expression levels of the interested genes were tested by Western blotting. 1×10
6
 cells were harvested after 
stimulation with the expressed heptapeptide KLWVIPQ and IFN-α for 48 h. After washed by PBS buffer, 
the cells were immediately placed on ice and lysed in 100 µL of cold radio immuno-precipitation assay 
(RIPA) lysis buffer at 4℃ for 15 min. The insoluble fraction was removed by centrifugation at 10000 g for 
20 min. The protein concentration was measured using Pierce BCA protein assay kit (Thermo, USA). 30 
µg of proteins for each lane was loaded onto 10% SDS-polyacrylamide gel. Following electrophoresis, the 
proteins were transferred onto polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was 
blocked by incubation in Tris-buffered saline containing 5% nonfat dry milk and 0.1% Tween 20 for 1 h at 
room temperature and then incubated at 4℃ overnight with the antibody of mouse anti-human P53 or 
P210
bcr/abl
 (Cell Signalling Technology Inc., USA). The PVDF membrane was washed three times in the 
Tris-buffered saline containing 0.1% Tween 20, and then incubated with the enhanced chemiluminescence 
labeled-antibody against mouse P53 antibody or P210
bcr/abl
 antibody (Beyotime, China) for 1 h. The PVDF 
membrane was washed again as described above and the bond antibodies were detected by using the 
enhanced chemiluminescence kit (Beyotime, China).    
Statistical analysis  
Experiments were repeated at least three times and the data were calculated as mean ± standard deviation. 
The data were analyzed using SPSS 16.0 software. Differences were analyzed using the paired-samples t 
test and the one-way analysis of variance (ANOVA) to compare the differences between groups.  
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Results 
Construction and transfection of recombinant expression vector pEGFP-KLWVIPQ 
The DNA fragment encoding the heptapeptide KLWVIPQ with a signal peptide sequence was inserted 
between the XhoI and AgeI restriction sites in the expression vector pEGFP-N1. To verify the insertion of 
the designed DNA fragment, PCR was conducted with specific primers using the plasmid DNA as template.  
As shown in Figure 1A, a fragment of DNA with expected size of 159bp was successfully amplif ied with 
the positive plasmid (lane 1), but PCR with the empty vector shown no amplification (lane 2).  Figure 1B 
showed the positive plasmid before (lane 1) and after the digestion with XhoI and AgeI (lane 2). The results 
from DNA sequencing (Figure 1C) demonstrated that the specific DNA sequence was successfully inserted 
into the plasmid vector as designed. To confirm that the recombinant plasmid pEGFP-KLWVIPQ was 
transfected into the KT-1/A3 and KT-1/A3R cells, RT-PCR was conducted. As shown in Figure 1D, the 
expected 159bp fragments were only amplif ied in the cells transfected with the positive clone (lanes 2 and 
5), not amplif ied in the cells either without transfection (lanes 1 and 4) or transfected with the empty vector 
(lanes 3 and 6). All together, these results demonstrated that we have not only constructed the plasmid 
containing the DNA encoding the heptapeptide, but also successfully transfected it into the KT-1/A3 and 
KT-1/A3R cells. 
 
Figure 1. Construction and characterization of the plasmid expressing KLWVIPQ 
(A) Agarose gel analysis of the PCR products amplified from positive (lane 1) and negative (lane 2) plasmids. Lane M: DNA 
molecular weight marker. (B) Agarose gel electrophoresis of the pEGFP-KLWVIPQ plasmid without (lane 1) and with (lane 
2) the digestions of XhoI  and AgeI.  (C) Sequencing results of the recombinant plasmid pEGFP-KLWVIPQ. (D) Agarose gel 
analysis of the PCR products amplified from the DNA purified from KT-1/A3 (lanes 1-3) and KT-1/A3R (lanes 4-6) cells  
under different transfection conditions. Lane1 and 4: without transfection, lane 2 and 5: transfected with pEGFP-KLWVIPQ, 
and lane 3 and 6 transfected with the empty vector pEGFP-N1. 
 
The effects of KLWVIPQ and IFN-α on the viability of KT-1/A3 and Kt-1/A3R cells 
The cells were either transfected with the expressing plasmid or treated with IFN-α alone or in 
combination and the number of viable cells was estimated. As shown in Figure 2，the viability of KT-1/A3 
cells was significantly reduced by either expressing the heptapeptide or IFN-α inducement comparing to 
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the non-treatment control (n=3, P<0.05). Transfection of the empty vector alone or in combination with 
IFN-α treatment has no effect on the cell viability. However, the repression effects of heptapeptide and 
IFN-α on cell viability canceled with each other when the cells were transfected with expression vector 
together with IFN-α treatment. Nevertheless, the above observed effects on the KT-1/A3 cells were not 
seen on the KT-1/A3R cells. Then we analyzed the apoptotic status of the cells under different treatments 
by flow cytometry. As shown in Figure 3, transfection of the empty vector has no effect on the apoptotic 
status of the cells. Transfection of the pEGFP-KLWVIPQ or treated with IFN-α alone increased the 
apoptotic cell population by 22.46% and 31.80%, respectively. However, the apoptotic cell population 
reduced to 9.87% when the cells were transfected with the pEGFP-KLWVIPQ and treated with IFN-α 
together. Similar as observed in the cell viability, these treatments to the KT-1/A3R cells showed no effect 
on the apoptotic population.  
 
 
Figure 2. The effects of KLWVIPQ expression and IFN-α on KT-1/A3 and KT-1/A3R cell viability (n=3) 
The KT-1/A3 and KT-1/A3R cells were transfected or treated with IFN-α and viable cells were estimated. 1: control; 2: 
transfection with pEGFP-KLWVIPQ; 3: transfection with pEGFP-N1; 4: IFN-α treatment; 5: transfection with 
pEGFP-KLWVIPQ and IFN-α treatment; 6: transfection with pEGFP-N1 and IFN-α inducement. * Significant difference 
between test and control groups. 
 
 
Figure 3. The effects of expressing KLWVIPQ or IFN-α treatment on KT-1/A3 and KT-1/A3R cell apoptosis  
The KT-1/A3 and KT-1/A3R cells were transfected either with pEGFP-KLWVIPQ or treated with IFN-α alone or in 
combination and analyzed by flow cytometry. Non-treatment or transfection with the empty vector served as negative 
controls. The apoptotic populations were indicated as percentages.  
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The effects of pEGFP-KLWVIPQ transfection and IFN-α treatment on gene expression  
The tumor suppressor P53 that functions to initiate cell cycle arrest and apoptotic pathways in many cells 
has been found to be up-regulated in response to IFN-α 
[9,28]
. P210
bcr/abl
 is characterized as the specific 
biomarker of CML and its expression level symbolizes the progression of CML 
[29]
. We were interested in 
understanding if the effects of the heptapeptide KLWVIPQ on KT-1/A3 cells were also P53- and 
P210
bcr/abl
-dependent. As shown in Figure 4A, P210
bcr/abl
 and P53 were down- and up-regulated by IFN-α 
in a dose-dependent manner comparing to the no-treatment control. Transfection of the pEGFP-KLWVIPQ 
to KT-1/A3 cell also down- and up-regulated P210
bcr/abl
 and P53, respectively. However, expression of the 
peptide KLWVIPQ counteracted the IFN-α effect on these genes. These effects were reproducible and 
statistically signif icance (Figure 4C). However, when the KT-1/A3R cells underwent the same treatments, 
the levels of P53 and P210
bcr/abl
 were affected minimally (Figure 4B, 4C and 4D). 
 
 
Figure 4. The levels of P53 and P210bcr/abl in KT-1/A3 and KT-1/A3R cells when  
transfected with pEGFP-KLWVIPQ and treated with IFN-α (n=3) 
KT-1/A3 (A) and KT-1/A3R (B) cells were either transfected with pEGFP-KLWVIPQ or treated with IFN-α alone or in 
combination, and the cell lysates were analyzed by western blot assays with antibodies against P53, P210 bcr/abl and GAPDH.  
The intensities of the bands were semi-quantified and ratios of P53/GAPDH and P210bcr/abl/GAPDH were plotted (C and D). 
The values showed were means ± standard deviation of triplicate experiments (*P<0.05). 1: control; 2: 1000U/ml of IFN-α; 
3: 3000 U/mL of IFN-α; 4: expression of KLWVIPQ; 5: expression of KLWVIPQ with 1000 U/mL of IFN-α; 6: expression 
of KLWVIPQ with 3000 U/mL of IFN-α. * Significant difference between the test and control groups. 
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Discussion    
The heptapeptide KLWVIPQ was previously identified during the screening of a phage display peptide 
library 
[27]
. This peptide specifically binds to the surface of the IFN-α-sensitive KT-1/A3 but not that of the 
IFN-α-resistant KT-1/A3R CML cells. Further sequence analyses found that this heptapeptide shares a 
partial sequence (LWVIP) homology with the C-terminal domain of the E3 ubiquitin-protein ligase. E3 
ligase is responsible for specific protein ubiquitination and subsequent degradation and therefore E3 ligase 
plays an important role in controlling the levels of various cellular proteins 
[30]
. Ubiquitination also serves 
as one of the major signaling pathways in determining apoptosis 
[31]
. In this study, we expressed this 
heptapeptide KLWVIPQ by transfecting the expressing plasmid into the IFN-α-sensitive KT-1/A3 and the 
IFN-α-resistant KT-1/A3R CML cell lines to decipher the roles of the heptapeptide KLWVIPQ in 
IFN-α-mediated effects on CML. Expressing this heptapeptide inhibited KT-1/A3 cell growth and induced 
apoptosis. However, expression of this peptide counteracted the IFN-α-regulated gene expression and 
KT-1/A3 cell apoptosis. Given the partial homology between this heptapeptide and E3 ligase, we 
postulated that this particular heptapeptide may alternate the IFN-α regulated P53 and P210
bcr/abl
 
expression by interfering with E3 ligase-mediated protein ubiquitination/degradation pathway. 
In order to avoid the detrimental effects from overreaction to type I IFN, a timely down-regulation of the 
response to type I IFN signal is needed and the HECT domain of ubiquitin E3 ligase RAUL is essential in 
this process. Zheng et al 
[32]
 suggested that IFN-α limits the extent of cellular responses to IFN-α by 
inducing the PKD2, and the activated PKD2 subsequently facilitates ubiquitination-mediated IFNAR1 
degradation through interacting with E3 ubiquitin ligase βTrcp. RAUL limits type I IFN production by 
directly catalyzing lysine 48-linked poly-ubiquitination of both interferon regulatory factor 7 (IRF7) and 
IRF3 followed by proteasome-dependent protein degradation 
[33]
. In addition, both ubiquitin E3 ligase Efp 
and interferon stimulated gene 15 (ISG15) were up-regulated by IFN in HepG2 and HeLa cells 
[34,35]
. In 
order to investigate the regulatory effects of the IFN-α-sensitive CML cell-binding heptapeptide 
KLWVIPQ partially homologized with E3 ligase to the related protein levels and cell growth of CML cells, 
a novel recombinant expression plasmid expressing secretive heptapeptide KLWVIPQ was established in 
the present study. After pEGFP-KLWVIPQ transfection in the condition with or without IFN-α inducement, 
the status of KT-1/A3 and KT-1/A3R CML cells in proliferation, apoptosis and the related protein levels 
were evaluated by using cell and molecular technologies. 
WST-1 cell proliferation analysis showed that proliferation of KT-1/A3 cells was suppressed when the cells 
were independently treated by pEGFP-KLWVIPQ transfection or IFN-α inducement. However, the 
suppression effects were reduced when the cells treated by pEGFP-KLWVIPQ and IFN-α together. 
Tingle-trial f low cytometry results indicate that either pEGFP-KLWVIPQ expression or IFN-α treatment 
can stimulate apoptosis of KT-1/A3 cells. However, like the inhibitory effects of pEGFP-KLWVIPQ and 
IFN-α to growth of KT-1/A3 cells, the effects of pEGFP-KLWVIPQ and IFN-α to apoptosis of KT-1/A3 
cells were reduced when they were used together. The reasons underlying such a phenomenon are obscure. 
The KT-1/A3R cells kept no response to the expressed peptide KLWVIPQ and/or IFN-α.    
P53 is a key regulator of apoptosis and also up-regulated by IFN 
[36]
. The tyrosine kinase protein P210
bcr/abl
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as the specific biomarker of CML is encoded by the bcr-abl fusion gene. Both P53 and P210
bcr/abl
 play 
critical roles in the pathogenesis and progression of CML 
[4]
. Additionally, inhibition of bcr-abl fusion gene 
expression has also been suggested as one of the mechanisms involved in IFN-α function for CML 
treatment 
[37]
. We found that IFN-α was able to up-regulate P53 and down-regulate P210
bcr/abl
 in the 
IFN-α-sensitive KT-1/A3 cells, but not the IFN-α-resistant KT-1/A3R cells. These results suggest that lost 
regulation to P53 and P210
bcr/abl
 could be one of the explanations for the CML resistance to IFN-α 
treatment. Interestingly, the heptapeptide KLWVIPQ showed similar effects on the expression of P53 and 
P210
bcr/abl
 in the IFN-α-sensitive KT-1/A3 cells, but not the IFN-α-resistant KT-1/A3R cells. Given the fact 
that this particular heptapeptide KLWVIPQ binds to the IFN-α-sensitive KT-1/A3 cells, it is likely that 
certain molecules responsible for the interaction with this particular heptapeptide specifically expressed on 
the surface of the IFN-α-sensitive KT-1/A3 cells. On the other hand, the IFN-α-resistant KT-1/A3R cells 
somehow managed to down-regulate the expression of these molecules which render the cells to escape the 
IFN-α-mediated cell death and therefore become IFN-α-resistant. If this proved to be true, identif ication 
and up-regulation of this molecule could become a valuable strategy in turning the CML cells from 
IFN-α-resistant to IFN-α-sensitive. In addition, since overexpression of the heptapeptide KLWVIPQ 
counteracted IFN-α-mediated regulation of P53 and P210
bcr/abl
 as well as KT-1/A3 cell apoptosis, we 
speculate that this heptapeptide and IFN-α compete with the same or similar cell surface binding site on 
the IFN-α-sensitive KT-1/A3 cells. Therefore, either this heptapeptide or IFN-α could be used as a bait in 
fishing the molecule specifically expressed on the surface of the IFN-α-sensitive KT-1/A3 cells. 
In summary, these results collectively demonstrated that the heptapeptide KLWVIPQ was capable of 
suppressing proliferation, accelerating apoptosis, up- and down-regulating P53 and P210
bcr/abl
 expression, 
respectively, for the IFN-α-sensitive KT-1/A3 CML cells but has no effects to IFN-α-resistant KT-1/A3R 
CML cells. Strategies inducing the expression of the specific molecule responsible for the binding of this 
peptide on the surface of IFN-α-resistant cells could make the cells become IFN-α-sensitive. Finally, this 
particular heptapeptide could be a novel target to go further into mechanisms of IFN-α action in CML. 
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